A congressional probe has faulted the Food and Drug Administration for failing to identify the companies responsible for contaminated heparin being imported from China to the United States, where it was linked to hundreds of deaths, according to a story in The Wall Street Journal Friday. http://online.wsj.com/article/SB10001424052748703572504575214420823549694.html?mod=WSJ_hpp_sections_news
That should come as no surprise to anyone with knowledge of that nightmarish heparin disaster. It’s rather obvious that the FDA was not doing its job, and still may not be doing its job in this regard, namely properly policing imported medicines and drugs.
Rep. Joe Barton, R-Texas, and Rep. Mike Burgess, R-Texas, in a letter to the FDA this week outlined the details of their investigation into the deadly heparin case. They told the agency that it had failed to follow up on several “specific and credible leads” that could have identified who was responsible for the contaminated blood thinner, The Journal reported.
Between 2007 and 2008 the contaminated imported heparin was tied to more than 80 deaths, and to hundreds of incidents where people fell sick.
Barton, the top Republican on the House Energy and Commerce Committee, has been spearheading the probe, and a vocal critic, of how the FDA handled the tainted heparin situation.
The letter to the FDA asserted that the federal agency hasn’t done any follow-up with the Chinese government on issues related to some Chinese companies, according to The Journal.
The investigation also found that the FDA didn’t investigation leads it received from foreign officials. For example, one November 2008 FDA memo said that a respectable foreign government agency had shared “a significant finding” that a Chinese business was manufacturing counterfeit heparin with plans to ship it to the United States under another company’s name, The Journal reported.
China is the source of much of the world’s crude heparin, as that country processes pigs intestines as an ingredient for that drug.
Back in March 2008, the FDA announced that it had identified the heparin contaminant. It was chondroitin suflate, which was mixed into the raw heparin in China “to stretch the supply,” according to The Journal.
The FDA never announced who it thought was responsible for the contamination. But there seemed to be several obvious culprits.
The letter cited the case of Chongqing Imperial Bio-Chem in China, which supplied pharmaceutical ingredients. An FDA document from April 2008 said that some of the crude heparin that Chongqing sent to an Ohio company was tainted, The Journal reported.
The FDA in March 2009 did ban pharmaceutical ingredients from Chongqing from coming to the states. But Barton and Burgress maintained that the agency should have probed further, in terms of Chonqging’s actual name and its place in the drug supply chain, according to The Journal.
The congressmen’s letter also pointed out that the FDA will have to overcome legal and language hurdles to conduct probes of drugs overseas